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Abstract 
Purpose: to evaluate the prognostic significance of clinical, biological and 
pathological features in angioimmunoblastic T-cell lymphoma (AITL). 
Methods: 157 patients with AITL were retrieved from the GELA LNH87 and LNH93 
trials. 147 patients received an anthracycline-based polychemotherapy. 
Histologically, 41 cases were classified as “rich in large cells” (> 10% T and/or B 
blasts) and 116 as “classic” (including 19 rich in epithelioid cells, 14 rich in clear cells, 
and 4 with hyperplastic germinal centers). 62 cases were evaluated for CD10 and 
CXCL13 expression and scored according to the abundance of positive lymphoid 
cells. 
Results: there was a male predominance. Median age was 62 years. 81%, 50% and 
67% of patients had an advanced stage, a non ambulatory performance status and 
an IPI>2 respectively. Anemia, hypergammaglobulinemia, and elevated LDH level 
were observed in 65%, 50% and 66% of patients respectively. CD10 and CXCL13 
were considered to be positive in atypical lymphoid cells, in 71% and 73% of cases 
respectively. With a median follow-up of 69 months, the 5y overall survival was 33%. 
In multivariate analysis, male gender (p=0.002), age ≤ 60y (p=0.008), mediastinal 
involvement (p=0.017) and anemia (p=0.021) were poor prognostic indicators for 
overall survival. IPI and PIT scores were not predictive of survival. Overall, “classic” 
and “rich in large cells” AITL subgroups were not different regarding clinical 
presentation and outcome.  
Conclusion: our large series emphasizes the morphologic heterogeneity of AITL, 
and confirms the common expression of CXCL13 and CD10 markers. AITL carries a 
poor prognosis and few prognostic factors. 
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Introduction   
Angioimmunoblastic T-cell lymphoma (AITL) represents a distinct clinicopathological 
entity, among nodal peripheral T-cell lymphomas (PTCL) (1). It generally occurs in 
elderly patients presenting with generalized lymphadenopathy, hepatosplenomegaly, 
anemia and hypergammaglobulinemia. Histological features of AITL include partial or 
complete effacement of the lymph node architecture by a polymorphous infiltrate that 
is typically associated with a proliferation of follicular dendritic cells (FDC) and a 
prominent arborization of high endothelial venules. The neoplastic cells are small to 
medium sized, display minimal cytological atypia and usually have a clear cytoplasm 
mostly in small clusters. They account for only a fraction of the infiltrate and are 
admixed with a reactive population of small lymphocytes, eosinophils, plasma cells, 
histiocytes and large lymphoid, sometimes Reed-Sternberg like B-cells which are 
often infected by Epstein-Barr virus (EBV) (2). AITL shows a morphological spectrum 
and increase in T-cell immunoblasts may be observed (1,3). Although it has not been 
thoroughly investigated, it was suggested that the increase in T-cell immunoblasts 
would indicate transformation into a peripheral T-cell lymphoma, unspecified 
(PTCL/U) (3). An increase in EBV-infected B-cells may also occur and in rare cases, 
an overt diffuse large B-cell lymphoma develops (4-6). The tumor cells usually 
express CD4, CD10, Bcl6 and CXCL13, a phenotype that is unique among T-cell 
lymphomas, suggesting their derivation from follicular helper T-cells (7-10). 
AITL is rare accounting for about 2% of all non-Hodgkin lymphomas (11). There have 
been relatively little data concerning the impact of clinical, biological and 
morphological features of angioimmunoblastic lymphadenopathy with dysproteinemia 
(AILD) and/or AITL on survival and outcome (12-18). In this report, we attempted to 
identify the prognostic significance of different pathological, biological and clinical 
parameters after a long follow-up of consecutive AITL patients treated with 
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chemotherapy according to LNH87 and LNH93 protocols conducted by the Groupe 
d’Etude des Lymphomes de l’Adulte (GELA). In particular, since rare cases of B-cell 
lymphomas have been reported to arise after AILD (4-5) and since it was suggested 
that the increase in T-cells could evolve into a PTCL/U (3), we intended to study the 
prognostic relevance of the increase (>10%) in large atypical cells, irrespective of 
their B or T-cell phenotype.  
 
Patients and methods 
Patient selection: 
Eligibility criteria for this study included patients with confirmed diagnosis of AITL 
after histopathological and immunohistochemical review. The 157 AITL patients are a 
subset of 6700 patients enrolled in the LNH87 and LNH93 GELA trials for 
intermediate and high grade lymphomas.  Part of the clinical features has been 
previously reported in 68 patients (19). 
 
Histological analysis: 
At the time of enrollment in the LNH87 and LNH93 protocols, lymph node biopsies 
were reviewed by pathologists of the GELA group and initially classified according to 
the Working Formulation (20) and updated Kiel classification (21), based on 
morphological examination of slides stained with hematoxylin-eosin and Giemsa and 
on immunohistochemistry comprising at least CD20 and CD3ε. For the purpose of 
the present study, four expert hematopathologists reviewed all T-cell lymphoma 
cases and completed the phenotype in order to reclassify them according to the 
WHO classification (1). In AITL cases, the diagnosis was based on the presence of 
the 5 following criteria: partial or diffuse effacement of the nodal architecture, 
vascular proliferation with prominent arborization of high endothelial venules, 
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extrafollicular meshwork of FDC, atypical population of CD3+ T cells, and large 
CD20+ B cells. 
To uncover the prognostic significance of the increase in large cells, cases were 
assigned to 2 major categories: “rich in large cells” (> 10% large B and/or T cells) and 
“classic”, the latter including cases rich in clear cells, rich in epithelioid cells, and with 
hyperplastic germinal centers (fig 1A-1E). 
 
Immunohistochemical analysis: 
           Immunohistochemistry was performed on deparaffinized tissue sections using an 
indirect immunoperoxidase method. After appropriate antigen retrieval, slides were 
stained for CD20, CD3ε and as far as possible CNA42 and/or CD21 antigens 
(DakoCytomation, Glostrup, Denmark). 36% of cases were tested for the presence of 
EBV using antibodies to latent membrane protein-1 (DakoCytomation) and/or in situ 
hybridization with probes specific for the EBV encoded small RNA (EBERs) 
sequences. Finally, 62 cases for which additional slides were available, were 
evaluated for CD10 (56C6; Novocastra, Newcastle, UK) and CXCL13 (R&D systems, 
Minneapolis, MN) expression and were assigned a score from 0 to 3 as follows (fig 
1F-1H); 0: negative/ very few positive lymphoid cells; 1: scattered lymphoid positive 
cells with no or one occasional aggregate; 2: many scattered positive lymphoid cells 
with more than one aggregate; 3: sheets of positive lymphoid positive cells. For 
detection of CXCL13 expression, an amplification system was used as recently 
reported (10). Positive internal control included polymorphonuclear leucocytes and 
residual germinal center B cells for CD10 and FDC and follicular helper T-cells for 
CXCL13. Cases without positive internal control were excluded from the analysis. 
 
Staging: 
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Patients were clinically staged according to the Ann Arbor classification. Initial 
investigations included a complete medical history and physical examination, 
computed tomography of the chest, abdomen and pelvis, bone marrow biopsy and 
biologic evaluation. Patients were randomized to treatment into one of the 4 groups 
of LNH87 and 7 groups of LNH93 protocols according to a score taking into account 
age and a number of prognostic factors of the age-adjusted International Prognostic 
Index (aaIPI) score (22). Patients were required to sign an informed consent 
approved by Hôpital Saint Louis, Paris- France institutional review board. They were 
excluded from the trial if they had positive serologic tests for HIV or HTLV1. 
 
Treatment: 
The results of both LNH87 and LNH93 protocols have in large part been published 
(23-31). Briefly, for younger patients, the reference arm was three to four courses of 
dose-intense doxorubicin, cyclophosphamide, vindesine, bleomycine, and 
prednisone (ACVBP) followed by sequential consolidation (76 patients) (31), and the 
experimental arm consisted of the following: eight cycles of methotrexate, bleomycin, 
doxorubicin, cyclophosphamide, vincristine and dexamethasone (mBACOD) in 
patients with no adverse factor (LNH 87-1, 11 patients) (23); four cycles of ACVBP-
like with a second randomization between sequential consolidation and high-dose 
chemotherapy (CBV) with stem cell rescue for patients under 56 years with at least 
one adverse factor (LNH 87-2, 7 patients) (24); four alternating induction cycles of 
teniposide, ifosfamide, mitoxantrone,  courses of etoposide, ifosfamide and 
mitoxantrone (VIM) and  doxorubicin, cyclophosphamide, vindesine and methotrexate 
(ACVM) in patients between 56 and 69 years with at least one adverse factor (LNH 
87-3, 14 patients) (25); three cycles of cyclophosphamide, doxorubicin, vincristine, 
prednisone (CHOP) with involved field radiotherapy for patients with 0 aaIPI factors 
H
AL author m
anuscript    inserm
-00282621, version 1
 9
(LNH 93-1, 2 patients) (26); four cycles of ACVBP-like followed by a modified 
consolidation for patients with 1 aaIPI factor (LNH 93-2, 2 patients); four cycles of 
ACVBP-like followed by high-dose chemotherapy with peripheral blood stem cell 
rescue for patients under 60 years with ≥ 2 factors (LNH 93-3, 17 patients) (27). 
For elderly patients, the arms were: four cycles of CHOP with or without additional 
involved field radiotherapy for patients with 0 aaIPI factors (LNH 93-4, 3 patients) 
(28); eight cycles of CHOP or ACVBP for patients under 70 years with 1-3 aaIPI 
factors (LNH 93-5, 12 patients) (29); six cycles of CHOP like or reduced CHOP for 
patients ≥ 70 years and PS < 2 (LNH 87- 4 and LNH 93- 6, 11 patients) (30); oral 
chemotherapy with etoposide, chlorambucil, and prednisone for patients ≥ 70 years 
with a PS ≥ 2 (LNH 93-7, 2 patients).  
Response to treatment was considered as complete (CR), unconfirmed complete 
(CRu), partial response or failure according to the International Workshop criteria 
(32). 
 
Statistical analysis: 
Patients’ characteristics and remission rates were compared using chi-squared test. 
Event-free survival (EFS) was defined as the time interval between randomization to 
primary treatment failure, relapse and death from any cause or last follow-up. Overall 
survival (OS) was defined as the time interval between randomization to last follow-
up or death from any cause. Estimates of survival were calculated according to the 
Kaplan-Meier method (33) and were compared using the log-rank test (34). Cox 
proportional-hazards regression analysis with OS and EFS as the dependent 
variables was used to detect potential independent prognostic factors. Differences 
were considered statistically significant when the two-sided p value was less than 
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0.05. All statistical analyses were performed using the Statistical Application System 
software (SAS, version 9, SAS institute, Cary, NC). 
 
Results 
Clinical and biological characteristics of AITL patients at presentation: 
Between April 1987 and October 1999, 157 patients were included in the study. 
Table 1 summarizes their main clinical and biological characteristics. The median age 
was 62 years (range 20 to 89 years). Most patients (126/156; 81%) presented with an 
advanced stage III-IV and 21 % (29/139) had > 2 extranodal involved sites. 
Laboratory investigations showed the presence of anemia in 65% (101/155) of 
patients, a positive Coombs test in 33% (30/92), hypergammaglobulinemia >12g/l in 
50% (73/146) and elevated serum LDH level in 66% (98/149). The international 
prognostic index (IPI) score was >1 in 89% (117/132) of patients and the prognostic 
index for PTCL/U (PIT) score (scoring system including age> 60y, performance 
status (PS)  ≥ 2, LDH ≥ normal and bone marrow involvement) (35) was >2 in 39% 
(56/144). 
 
Pathological findings: 
By definition, all cases displayed FDC hyperplasia demonstrated by morphology 
and/or CNA42/CD21 immunostaining, as well as a variable proportion of CD20 large 
B cells within an atypical T-cell population. In addition, most of the tested cases 
disclosed EBV positive cells. According to their cytological aspect, 41 cases were 
classified as “rich in large cells” and 116 as “classic” (Table 2) including 19 rich in 
epithelioid cells, 14 rich in clear cells and 4 with hyperplastic germinal centers. 
Among the 62 cases interpretable for CD10 expression, 71% (n=52) disclosed 
aggregates or sheets of CD10 positive cells with atypical features (scored 2+3). 
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Scattered CD10 positive lymphoid cells (score 1) - the neoplastic nature of which 
could not be determined - were observed in 12% and CD10 was negative (score 0) in 
17% of our cases. 45 out of 62 sections were adequate for CXCL13 interpretation. 
CXCL13 staining was found, as a dot reinforcement of the Golgi area, in aggregates 
or sheets of atypical cells (score 2+3) in 73% of cases, and in scattered lymphoid 
cells (score 1) in the remaining 27%. Overall, at least one marker was scored positive 
in 86% of the interpretable cases and both markers were negative in 14% of them. 
 
Clinical outcome and prognostic parameters: 
All but 10 patients received an anthracycline-based chemotherapy. CR/CRu was 
achieved in 46% of patients after induction therapy and 41% were in CR/CRu at the 
end of therapy. Overall, the two populations “classic” and “rich in large cells” were not 
statistically different in terms of clinical features, laboratory findings and treatment 
response (p=0.676) except for a higher frequency of elevated serum LDH (p=0.027) 
and β2 microglobulin levels (p=0.046) within the group “rich in large cells”. 
Furthermore, no difference could be observed between the different 
chemotherapeutic regimens, whether the treatment was considered intensive or not. 
Follow-up could be assessed in 156 patients. The median follow-up was 68 months 
(3.77-161.47). The 2, 5 and 7-year OS rates were 51% (CI, 42.85-58.77), 33% (CI, 
25.63-40.95) and 29% (CI, 21.19-36.73) respectively, fig (2A), reaching a plateau 
level around 6 years. The 2, 5 and 7-year EFS rates were 38% (CI, 30.66-46.06), 
29% (CI, 21.54-36.02) and 23% (CI, 15.57-29.94) respectively, fig (2B). The 
distribution of OS and EFS curves was not statistically different between the groups, 
“classic” and “rich in large cells”, fig (3). In univariate analysis, male gender 
(p=0.004), mediastinal involvement (p=0.014) and anemia (p=0.048) were poor 
prognostic factors for OS (Table 1). Multivariate analysis (Table 3) showed that male 
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gender (p=0.002), age ≤ 60y (p=0.008), mediastinal involvement (p=0.017) and 
anemia (p=0.021) were independent prognostic factors for OS. OS differed 
significantly in favor of patients who developed CR/CRu (p<0.0001). IPI and PIT 
scores were not predictive of survival (fig 4). The different histological subtypes as 
well as CD10 and CXCL13 scoring did not have any influence on survival. 
 
Discussion 
In the present series of 157 AITL patients - the largest reported so far in which 
patients were included in randomized clinical trials - we further extend the peculiar 
clinical and biological findings of AITL and confirm its poor prognosis despite a first-
line anthracycline-based chemotherapy with a curative intent in most patients. We 
also emphasize its morphologic heterogeneity as well as the common expression of 
CD10 and CXCL13 determined on routinely-fixed samples.  
In keeping with previous reports (12-18, 36-38), we observed that AITL is a disease 
of the elderly presenting with systemic manifestations and features known to be poor 
prognostic factors for B-cell lymphomas: 54% of our patients were more than 60 
years old, 50% had an altered PS, 81% presented with stage III-IV disease, 46% had 
more than one extranodal site involvement and 66% had an elevated LDH level. The 
clinical symptoms and biological signs are not specific of AITL but their association 
appears to be very suggestive of the disease. Notably, skin rash (44%), 
arthritis/arthralgia (16%), pleural effusion/ascites/edema (26%), 
hypergammaglobulinemia (50%) and positive Coombs test (33%) appear to 
represent distinctive manifestations of AITL. 
A small number of studies sought to identify prognostic factors in AITL/AILD (12-18), 
yielding controversial results. Their results might be hampered by the relatively 
limited number of patients and/or the heterogeneous therapies including 
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prednisolone alone in a proportion of these patients. In the recent literature where the 
entity was considered as lymphoma, one study (15) found that survival was 
influenced by age, stage and number of symptoms including B symptoms, 
rash/pruritus, and LDH and hemoglobin levels, whereas other studies (16-18) found 
no reliable clinico-biological prognostic indicator for the disease. In the current study, 
where overall patients received more intensive chemotherapy compared to these 
previous reports, multivariate analysis showed that male gender (p=0.002), age ≤ 60y 
(p=0.008), mediastinal involvement (p=0.017) and anemia (p=0.021) were poor 
prognostic factors for OS. IPI, extensively used for B-cell lymphomas patients, has 
also been found to be of prognostic value in some PTCL series comprising AITL and 
other T-cell lymphomas entities (19, 39-41). In keeping with a previous study focusing 
on AITL (18), we found that IPI is not a significant predictor of survival (p=0.799). The 
prognostic model “PIT” proposed by Gallamini et al for PTCL/U was neither predictive 
of survival in the present series (p=0.106) (35). Moreover, in a previous study 
published by GELA (19), hypergammaglobulinemia > 20 g/l and eosinophilia ≥ 
0.8x109/l were more often encountered in AITL than in other subtypes of T-cell 
lymphomas. Overall, these data reinforce the idea that AITL is a distinct entity. Since 
IPI and hypergammaglobulinemia/ eosinophilia are supposed to reflect tumor load 
and immune dysregulation respectively, this may suggest that AITL related 
manifestations would more likely reflect immune dysregulation than tumor burden (7-
9). The impact of the clinicopathological prognostic index (including age, 
LDH>normal, non ambulatory PS, Ki67 ≥ 80%) described by Went et al (42) for 
PTCL/U patients could not be assessed in our AITL series. 
 
In the present series, we emphasize the morphologic heterogeneity of AITL, which 
could be a source of misdiagnosis to poorly experienced pathologists, especially 
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concerning cases with hyperplastic germinal centers and rich in epithelioid cells, the 
latter can be mistaken as Lennert's lymphoma or Hodgkin lymphoma. This is 
reflected by the large error rate (50%) in the referred cases described by Attygalle et 
al (7) and by our very low recruitment of cases with hyperplastic germinal centers, a 
pattern which has recently received attention since it was described in 1998 (43). 
Few reports have tried to identify histological prognostic features, but none of them 
are of proven clinical value. Nathwani and colleagues (44) first noticed in 1978 that 
the presence of cohesive foci of immunoblasts in AILD, was associated with poorer 
outcome and more widespread disease at autopsy. More recently, Lee SS et al (18) 
identified two histological groups based on the absence or presence of large atypical 
T blasts or clusters of clear cells and found no statistical difference between these 
two groups in terms of clinical and laboratory findings and survival. The prognostic 
relevance of “the presence or absence” of clear cells was studied by two other 
groups (14,16) but their results are contradictory. We consider, however, the “mere 
presence” of clear cells to represent part of the morphologic features of AITL, and the 
“abundance” of clear cells did not influence survival in the present study (data not 
shown). The current study specially attempted to investigate the potential prognostic 
relevance for the increase in large cells, but it failed to show any significance on 
outcome for this increase. In this respect, the number of CD10 and CXCL13 positive 
atypical cells, which is supposed to represent the neoplastic counterpart, did not 
show any influence on survival. 
It has been recently shown that CXCL13, a chemokine critically involved in B-cell 
migration into germinal centers, was highly up-regulated in the follicular T helper cell 
subset (45-47). Subsequently, we and others have shown that CXCL13 was 
expressed by neoplastic cells of most AITLs (9-10). CD10 and CXCL13 were 
proposed as sensitive immunohistochemical markers in AITL (7,9,10). This finding 
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was confirmed in the present study where at least one marker stained clusters of 
atypical lymphocytes in the majority (86%) of cases. However, in the few cases 
(14%) where it was difficult to assign the neoplastic nature for the rare scattered 
stained cells on pure morphological grounds, both markers were considered 
negative. In such circumstances, the diagnosis of AITL should rely on a combination 
of classical morphological criteria together with clinical and biological features.  
 
Despite of various intensive regimens with an anthracycline-based chemotherapy, 
AITL, compared to other non-Hodgkin lymphomas, pursues an aggressive clinical 
course, so the optimal therapeutic regimen remains to be determined. AITL does not 
present any pertinent prognostic factor besides, naturally, the achievement of a 
complete response to therapy. However, after a long follow-up, we observed a trend 
for a plateau level reaching a survival probability of around 30% at 6 years. A longer 
follow-up is further needed to determine whether these patients are eventually cured 
of their disease.  
H
AL author m
anuscript    inserm
-00282621, version 1
 16
Figure legends 
Figure 1: Figures A to E illustrate angioimmunoblastic lymphoma sub-types: (A) 
“classic-type”, (B) “rich in large cells”, (C) with hyperplastic germinal centers, (D) rich 
in clear cells, (E) rich in epithelioid cells (hematoxylin eosin); Figures F to G illustrate 
CXCL13 immunostaining patterns, i.e. score 1 (F), score 2 (G) and score 3 (H) . 
Figure 2: Overall survival (A) and event-free survival (B) of the 156 patients with 
angioimmunoblastic T-cell lymphoma. 
Figure 3: Overall survival of patients with “classic” AITL compared to patients with 
AITL “rich in large cells”. 
Figure 4: Overall survival of angioimmunoblastic T-cell lymphoma patients according 
to IPI (A) and PIT (B) scores. 
Table 1: Clinico-biological characteristics of AITL patients and their relevance on 
overall survival 
Table 2: Histopathologic and phenotypic characteristics of AITL patients and their 
correlation with overall survival (to be published online only) 
Table 3: Parameters influencing survival of AITL patients in multivariate analysis 
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Table 1 
 
Characteristics Number Percentage p value 
 
Gender     0.004* 
    Male   95/157 60  
    Female 62/157 40  
Age   0.072 
    Median 62   
    Range 20-89   
    <60 72/157   
    >60 85/157   
Performance status    0.721 
    0-1 79/157 50  
    >1 78/157 50  
B symptoms 112/155 72 0.127 
Ann Arbor Stage   0.426 
    I-II 30/156 19  
    III-IV 126/156 81  
Bulky >10 cm 27/102 26 0.132 
Number of extranodal sites   0.096 
    0-1 75/139 54  
    >1 64/139 46  
Extranodal involvement       
    Liver 38/154 25 0.132 
    Spleen 86/155 55 0.145 
    Mediastinum 86/153 56 0.014* 
    Skin 46/154 30 0.267 
    Lung 15/153 10 0.546 
    Bone marrow 71/151 47 0.775 
Effusion/edema/ascites 16/62 26 0.895 
Polyarthritis/arthralgia 12/76 16 0.810 
Skin rash 36/82 44 0.598 
IPI score   0.799 
    0-1 15/132 11  
    2-3 67/132 51  
    4-5 50/132 38  
PIT score   0.106 
    0-1 38/144 26  
    2 50/144 35  
    3-4 56/144 39  
Anemia (Hb ≤ 12g/dl)                           101/155 65 0.048∗ 
Positive Coombs test                           30/92 33 0.300 
Lymphopenia <= 700/µl                       77/156 49 0.065 
Thrombocytopenia ≤ 150/ µl                33/121 20 0.220 
Hypereosinophilia > 500/ µl                 12/38 32 0.373 
Hypergammaglobulinemia >12g/l        73/146 50 0.260 
Serum LDH level > normal                   98/149 66 0.794 
Hypoalbuminemia <35g/l                     71/143 50 0.162 
Serum β2 microglobulin level >3mg/l   71/107 66 0.911 
 
 
AITL: angioimmunoblastic T-cell lymphoma 
IPI: International prognostic index (age, performance status, stage, LDH) 
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PIT: Prognostic index for peripheral T-cell lymphoma, unspecified (age, performance status, 
bone marrow involvement, LDH) 
 
 
 
Table 2 (to be published online only) 
 
Pathological findings                      Number Percentage p value 
 
Classic                                               116 74 0.552 
    Rich in epithelioid cells                  
 
19 13  
    Rich in clear cells                          
 
14 9  
    With hyperplastic germinal 
centers                   
04 03  
Rich in large cells                              
 
41 26  
    
CD10                                                 
 
52  0.652 
    Score 0                                          
 
09 17  
    Score 1                                          
 
06 12  
    Score 2                                          
 
25 48  
    Score 3                                          
 
12 23  
    
CXCL13                                             
 
45  0.865 
    Score 0                                          
 
0 0  
    Score 1                                          
 
12 27  
    Score 2                                          
 
24 53  
    Score 3                                          09 20  
 
 
 
 
 
Table 3 
 
Parameter p relative risk 95% CI low 95% CI high 
 
Age ≤ 60y                        0.008 1.712 1.150 2.549 
Male gender                    0.002 1.921 1.258 2.934 
Anemia (Hb ≤ 12g/dl)      0.021 1.681 1.082 2.613 
Mediastinal 
involvement    
0.017 1.662 1.097 2.521 
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Figure 1 
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